ESR1 and breast cancer: ODX testing, also known as the 21‐gene assay, is the most widely used BC genomic assay in the world; it is supported by the American Society of Clinical Oncology and the National Comprehensive Cancer Network for decision‐making about the treatment of node‐negative, ER‐positive BC patients and is accepted as a clinically valuable test [28, 29, 30].